| Literature DB >> 29103586 |
Zahra Asadzadeh1, Hamed Mohammadi1, Elham Safarzadeh1, Maryam Hemmatzadeh1, Ahmad Mahdian-Shakib2, Farhad Jadidi-Niaragh1, Gholamreza Azizi3, Behzad Baradaran4.
Abstract
Immune system acts as a host defensive mechanism protecting against attacking pathogens and transformed cells, including cancer cells. Th17 cells are a specific subset of T helper lymphocytes determined by high secretion of IL-17 and other inflammatory cytokines. Th17 cells increase tumor progression by activating angiogenesis and immunosuppressive activities. They can also mediate antitumor immune responses through recruiting immune cells into tumors, stimulating effector CD8+ T cells, or surprisingly by altering toward Th1 phenotype and producing IFN-γ, so Th17 cells are supposed as a double-edged sword in cancer. A comprehensive approach to indicating the activity of Th17 cells in tumor progression could help in the planning of new therapeutic approaches specially targeting Th17 cells in cancer.Entities:
Keywords: Angiogenesis; Anti-tumor; IL-17 cytokine; Pro-tumor; Th17 cells
Mesh：
Substances：
Year: 2017 PMID： 29103586 DOI： 10.1016/j.cellimm.2017.10.015
Source DB: PubMed Journal: Cell Immunol ISSN： 0008-8749 Impact factor: 4.868